Evidence map›Paper›PMID 28134057›Full record

Trial reportHIV clinical trials2017

HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.

Maile Y Karris, Sonia Jain, Tyler R C Day, Josué Pérez-Santiago, Miguel Goicoechea, Michael P Dubé, Xiaoying Sun, Celsa Spina, Eric S Daar, Richard H Haubrich and 2 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in HIV clinical trials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Maile Y Karrisa Department of Medicine , University California San Diego , San Diego , CA , USA.
Sonia Jainb Department of Family and Preventive Medicine , University California San Diego , San Diego , CA , USA.
Tyler R C Dayc Department of Medicine , Washington University , Saint Louis , MO , USA.
Josué Pérez-Santiagoa Department of Medicine , University California San Diego , San Diego , CA , USA.
Miguel Goicoechead Department of Medicine , Scripps Health San Diego , CA , USA.
Michael P Dubée Department of Medicine , University Southern California Keck School of Medicine , Los Angeles , CA , USA.
Xiaoying Sunb Department of Family and Preventive Medicine , University California San Diego , San Diego , CA , USA.
Celsa Spinaf Department of Pathology , Veterans Affairs San Diego Healthcare System , San Diego , CA , USA.
Eric S Daarg Los Angeles Biomedical Research Institute , Harbor-UCLA Medical Center , Los Angeles , CA , USA.
Richard H Haubrichi Gilead Sciences , Forest city , CA , USA.
Sheldon Morrisa Department of Medicine , University California San Diego , San Diego , CA , USA.
California Collaborative Treatment Group (CCTG) 589 Study Team
University of California, San Diego · USGilead Sciences (United States) · USHarbor–UCLA Medical Center · USScripps Health · USUniversity of Southern California · USVA San Diego Healthcare System · USWashington University in St. Louis · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
Efficacy of ART to Interrupt HIV Transmission NetworksR01MH100974 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2014 to 2018
$3.2M
Screening for atherosclerotic vascular disease in HIV-infected childrenR01HD083042 · NICHD · STELLENBOSCH UNIVERSITY · PI HAUBRICH, RICHARD H, INNES, STEVE · 2015 to 2019
$1.6M
NIAID NIH HHS P30 AI036214NIAID NIH HHS R24 AI106039NICHD NIH HHS R01 HD083042NIMH NIH HHS R01 MH100974
6 · The paper itself

Abstract

backgroundNucleos(t)ide reverse transcriptase inhibitor (NRTI)-sparing regimens may potentially minimize antiretroviral (ART) toxicities, but demonstrate mixed efficacy and toxicity results. The impact of an integrase strand transfer inhibitor (INSTI) and protease inhibitor (PI) regimen on HIV viral dynamics and T cell kinetics remains underdescribed.

objectiveTo compare the effect of raltegravir + ritonavir boosted lopinavir (RAL + LPV/r) to efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) on HIV kinetics and T cell dynamics.

methodsFifty participants naïve to ART underwent HIV viral kinetic sampling evaluated using biexponential mixed effects modeling. A subset of 28 subjects (with complete viral suppression) underwent flow cytometry and evaluation of soluble markers of inflammation at weeks 0, 4, and 48 of ART.

resultsRAL + LPV/r compared to EFV/TDF/FTC resulted in a prolonged first phase viral decay rate (18 vs. 13 days p < 0.01). From weeks 0 to 4, RAL + LPV/r was associated with a trend toward greater decreases in activated CD4

conclusionsThe prolonged first phase viral decay observed with RAL + LPV/r in persons starting ART did not result in differences in viral suppression at week 48. We also observed trends in declines in certain cellular markers of immune activation but it remains unclear if this could translate to long-term immunologic benefits in persons on an INSTI + PI.

Indexed as

Viral LoadAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBiomarkersCD4 Lymphocyte CountFemaleHIV InfectionsHIV Protease InhibitorsHumansImmunologic MemoryLymphocyte ActivationMaleMiddle AgedRisk FactorsTime FactorsAnti-HIV AgentsBiomarkersHIV Protease InhibitorsAntiretroviral naïveCCTG 589Immune activationINSTI-PI regimenNRTI sparingT cell dynamicsViral kinetics

Identifiers

PMID28134057
PMCPMC5613656
OpenAlexW2582221181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.